doctor head
 
  pharmacy and drugs  
search Search
 
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
 
  doctor legs  
 
 
 
 

  Diseases

  Newsletter
Subscribe to our newsletter:
Name:
E-mail:
    Search results
Search results for: adderall

1 - 3 of 3 <<previous | next>>

Drugs results:

Adderall tablets

Adderall

Adderall (also known as Dextroamphetamine and amphetamine) is one of a group of medicines known as Central Nervous System (CNS) stimulants. They are used to treat Attention-Deficit Hyperactivity Disorder (ADHD). Amphetamines are also more...

Modafinil

Modafinil

Modafinil improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and shift work sleep disorder (SWSD); adjunctive therapy for obstructive sleep apnea/hypopnea syndrome (OSAHS). more...

Diseases results:

Sleep disorder
Narcolepsy

Articles results:

New Study Supports Low Abuse Potential Of Leading ADHD Medication, CONCERTA® (methylphenidate HCl)
Results of a new study found that an extended-release form of methylphenidate - sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists.


ADHD Drug Makers To Notify Patients About Health Risks
Makers of drugs approved to treat Attention Deficit Hyperactivity Disorder (ADHD) have been instructed by the US Food and Drug Administration (FDA) to notify patients of certain health risks.The manufacturers affected include Eli Lilly and Co, Novartis AG, Johnson & Johnson, and Shire plc.


Novel Treatment For ADHD - Shire And New River Pharmaceuticals Announce FDA Approval Of The First And Only Stimulant Prodrug VYVANSE
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). On February 20, 2007 Shire and New River announced an agreement whereby Shire will acquire New River for approximately $2.




1 - 3 of 3 <<previous | next>>

© 2006-2010 pharmacy-and-drugs.com. All rights reserved.